Related Experiment Video
Updated: Nov 2, 2025

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
Published on: November 3, 2023
Balanced Salt Solution Versus Normal Saline in Resuscitation of Pediatric Sepsis: A Randomized, Controlled Trial
Sirawut Trepatchayakorn1, Manee Sakunpunphuk2, Rujipat Samransamruajkit3
1Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, Pathum Wan, Bangkok, 10330, Thailand. sirawut.t@chula.ac.th.
Insights
Pediatric sepsis resuscitation with normal saline solution (NSS), Ringer lactate solution (RLS), or Sterofundin showed no significant differences in complications. However, a large dose of RLS was linked to reduced urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels.
Area of Science:
- Pediatric critical care medicine
- Resuscitation science
- Fluid therapy
Background:
- Current evidence on crystalloid fluid resuscitation in adult sepsis is extensive, yet data specific to pediatric populations remains limited.
- Understanding the impact of different crystalloid solutions on pediatric sepsis resuscitation outcomes is crucial for clinical practice.
Purpose of the Study:
- To compare the resuscitation outcomes of pediatric sepsis patients treated with normal saline solution (NSS), Ringer lactate solution (RLS), or Sterofundin.
- To investigate the association between crystalloid type and complications in pediatric sepsis resuscitation.
Main Methods:
- A randomized trial involving 42 pediatric sepsis patients requiring fluid bolus therapy.
- Patients were assigned to receive either NSS, RLS, or Sterofundin.
- Outcomes, including complications and urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels, were assessed post-fluid bolus.
Main Results:
- No significant differences in complications were observed among the three crystalloid groups after fluid bolus.
- Patients in the RLS group who received a large fluid dose demonstrated a significant reduction in uNGAL levels.
- This suggests a potential benefit of RLS in reducing a specific biomarker of kidney injury in pediatric sepsis.
Conclusions:
- Fluid bolus therapy with NSS, RLS, or Sterofundin did not lead to different overall resuscitation outcomes in pediatric sepsis.
- Higher doses of RLS may be associated with a greater reduction in uNGAL levels compared to other crystalloids, indicating a potential role in mitigating kidney stress.
Abstract:
Current evidences in resuscitation of adult sepsis have pointed to the importance of types of crystalloid fluid-related complications on resuscitation outcomes, but evidences are lacking in pediatric populations. In this study, the authors aimed to compare outcomes of pediatric sepsis resuscitation with different types of crystalloid. They randomly assigned pediatric sepsis patients requiring fluid bolus into three groups to receive either normal saline solution (NSS), Ringer lactate solution (RLS), or Sterofundin as fluid bolus therapy. Forty-two patients were included in the study. Median age was 29 mo and, weight 13 kg. After fluid bolus, the complications were not different among groups. However, in the RLS group, the patients who received large dose of the fluid showed significant reduction in urinary neutrophil gelatinase-associated lipocalin (uNGAL) level. It is concluded that fluid bolus therapy with different types of crystalloid solution did not result in different outcomes but large dose of RLS was associated with greater reduction of uNGAL level, compared to other fluids.Trial Registration: Thai Clinical Trial Registry (TCTR) identification number TCTR20170605001 (retrospectively registered on 1st June 2017). https://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task20=search&task2=view1&id=2576.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

